Literature DB >> 8793465

Pleuropulmonary changes induced by ergoline drugs.

P Pfitzenmeyer1, P Foucher, G Dennewald, B Chevalon, D Debieuvre, P Bensa, F Piard, P Camus.   

Abstract

Classic ergolines, such as bromocriptine, methysergide and ergotamine, can induce chronic pleuropneumonitis. We present the cases of eight patients who developed similar changes whilst on other ergolines. In this retrospective case study spanning 1985-1995, clinical data, radiological material, pulmonary function, bronchoalveolar lavage and histopathology were reviewed. Earlier literature on ergoline-induced pleuropulmonary changes was reviewed. Eight middle-aged to elderly individuals of both sexes developed pleuropulmonary changes during long-term therapy with regular dosages of nicergoline (n = 4), dihydroergocristine (n = 3), or dihydroergotamine (n = 1). Bibasilar pleural thickening with or without pleural effusion was present on chest radiographs and computed tomographic (CT) scans in six cases. Increased erythrocyte sedimentation rate was seen in most. Pure interstitial pneumonitis developed in two patients on dihydroergocristine and was reversible in each. Bronchoalveolar lavage was performed in four cases and was abnormal in all, but demonstrated no consistent pattern. Most patients exhibited lung restriction. The outcome was favourable showing slow improvement in all cases following discontinuation of the ergoline. Slight residual pleural thickening was seen in five out of the six cases with pleural involvement. Nicergoline and dihydroergotamine can induce a syndrome of chronic pleural thickening/effusion that slowly improves after drug withdrawal. Dihydroergocristine can induce reversible interstitial pneumonitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8793465     DOI: 10.1183/09031936.96.09051013

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Investigating a case of recurrent pleural effusion.

Authors:  Patrícia Rodrigues; Maria Neves; João Pedro Ferreira; Miguel Araújo Abreu; Fernanda Almeida
Journal:  Case Rep Pulmonol       Date:  2011-10-15

Review 2.  Retroperitoneal fibrosis - the state-of-the-art.

Authors:  Marta Runowska; Dominik Majewski; Mariusz Puszczewicz
Journal:  Reumatologia       Date:  2016-11-28

3.  Medical Challenge Posed by Retroperitoneal Fibrosis: Case Reports and Literature Review.

Authors:  Sergio Cervera-Bonilla; Mauricio Garcia Mora; Paola Rodriguez Ossa; Oscar Messa; Sara Mendoza Díaz
Journal:  Cureus       Date:  2020-01-10

4.  Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.

Authors:  Trevor Archer; Tomas Palomo; Robert McArthur; Anders Fredriksson
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

5.  Asbestos-related pleural and lung fibrosis in patients with retroperitoneal fibrosis.

Authors:  Toomas Uibu; Ritva Järvenpää; Jari Hakomäki; Anssi Auvinen; Eero Honkanen; Kaj Metsärinne; Pekka Roto; Heikki Saha; Jukka Uitti; Panu Oksa
Journal:  Orphanet J Rare Dis       Date:  2008-11-13       Impact factor: 4.123

Review 6.  Safety of nicergoline as an agent for management of cognitive function disorders.

Authors:  Bernd Saletu; Amit Garg; Ahsan Shoeb
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.